HROW - Harrow Health, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.8200
-0.3200 (-7.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.1400
Open4.1300
Bid0.0000 x 900
Ask7.0000 x 800
Day's Range3.8000 - 4.1300
52 Week Range3.3300 - 8.9900
Volume425,266
Avg. Volume176,579
Market Cap97.513M
Beta (5Y Monthly)0.33
PE Ratio (TTM)545.71
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine Services

    Harrow Health, Inc. (HROW) and ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow, announced that they have entered into an exclusive agreement with Doxy.me, a full-service telemedicine solution. Doxy.me is one of the largest, yet simplest, telemedicine software solutions in the world, providing video, audio and text through which patients and healthcare providers can seamlessly communicate remotely.

  • GlobeNewswire

    Harrow Health Appoints Teresa Sparks to its Board of Directors

    Harrow Health, Inc. (HROW) today announced the appointment of Teresa Sparks to its Board of Directors. As Harrow continues to drive shareholder value by founding, developing, and deconsolidating companies like Eton, Surface, and Melt, I anticipate Teresa’s impressive experience as a healthcare leader of both private and publicly traded companies will be an invaluable asset.

  • GlobeNewswire

    Harrow Health Publishes Fourth Quarter 2019 Letter to Stockholders

    The company is not expecting disruptions in its business or supply chain as a result of the recent COVID-19 virus concerns in the US and around the world. The company has double checked inventories and its sources of key active pharmaceutical ingredients and other materials. In addition, the company has been in contact with its insurance provider and believes it has adequate coverage through its various risk management policies that could help supplement any losses in the unlikely event a potentially recoverable claim was to occur.

  • GlobeNewswire

    ImprimisRx® Announces Supply Agreement with EyeCare Services Partners

    ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that it has agreed to a product supply agreement with EyeCare Services Partners (ESP). ImprimisRx currently provides a limited number of ophthalmic formulations to practices within the ESP group, but this agreement will expand the number of formulations available to new and existing ESP facilities and allow for additional formulations to be added as the ImprimisRx/ESP relationship continues to expand. ESP is a partnership of 30+ ophthalmologic, optometric brands, and ambulatory surgery centers (ASCs) across multiple states, with 90 locations, 12 ASCs, and 200 providers, representing approximately 100,000 ophthalmic procedures in the U.S. annually.

  • GlobeNewswire

    ImprimisRx® Announces Supply Agreement with iOR Partners

    ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that it has agreed to a product supply agreement with iOR Partners. Under the agreement, ImprimisRx will provide a variety of formulations needed for in-office surgeries, including the MKO Melt® and various injectable and topical products.

  • GlobeNewswire

    ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA)

    ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that it has agreed to a product supply agreement with Vision Center Network of America, LLC (VCNA). The agreement will make ImprimisRx a VCNA preferred provider for a variety of surgical formulations, including a portfolio of topical and injectable products.

  • GlobeNewswire

    Harrow Health to Announce Fourth Quarter 2019 Financial Results on March 13, 2020

    Harrow Health, Inc. (HROW) today announced that before the open of trading on Friday, March 13, 2020, it will release fourth quarter 2019 financial results and host a conference call at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time to discuss the financial results and recent business developments. Prior to the open of the market on March 13, 2020, at approximately 8:00 a.m. Eastern Daylight Time / 5:00 a.m. Pacific Daylight Time, Harrow will issue a press release containing a link to its fourth quarter 2019 Letter to Stockholders. On the conference call, the primary objective is to allow analysts to engage in a question and answer session with the Harrow management team after providing a brief introduction and overview of the quarter and outlook for the business.

  • PR Newswire

    Inventor Of "LessDrops," Surgical Eyedrop, Wins Return Of Patent From Harrow Health

    Novel Drug Solutions, LLC and Eye Care Northwest, PA, announce the return of their unrestricted patent rights to several awarded and pending USA and international patents previously controlled by Harrow Health, Inc. (NASDAQ: HROW formerly known as Imprimis Pharmaceuticals, Inc.).

  • GlobeNewswire

    ImprimisRx’s FDA-Registered Outsourcing Facility Issued California License

    ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California. This license allows California-based ophthalmologists, optometrists, surgery centers and hospitals to efficiently order and stock ImprimisRx’s more than 40 ophthalmic products for on-demand administration to their patients.

  • GlobeNewswire

    Harrow Health Publishes Third Quarter Letter to Stockholders

    NASHVILLE, Tenn., Nov. 13, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2019.  Please click here to review Harrow Health’s.

  • GlobeNewswire

    Harrow Health to Announce Third Quarter 2019 Financial Results on November 13, 2019

    Harrow Health, Inc. (HROW) today announced that after the close of trading on Wednesday, November 13, 2019, it will release third quarter 2019 financial results and host a conference call at 5:00 p.m. Eastern Standard Time / 2:00 p.m. Pacific Standard Time to discuss the financial results and recent business developments. After the close of the market on November 13, 2019, Harrow will issue a press release containing relevant financial results and a link to a Letter to Shareholders.

  • GlobeNewswire

    Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors

    Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (HROW), today announced David Adair, M.D. will join the Mayfield Pharmaceuticals Board of Directors. Dr. Adair is a Co-Founder and Managing Director of Solas BioVentures, a venture capital fund that invests exclusively in the Life Sciences industry. Dr. Adair has extensive experience serving as a director on the boards of several pharmaceutical and medical device companies, including companies specializing in women’s health, in addition to 21 years as an OB/GYN Department Professor and Vice Chairman at the University of Tennessee College of Medicine in Chattanooga.

  • GlobeNewswire

    Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019

    BOSTON, Oct. 08, 2019 -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief Executive Officer,.

  • GlobeNewswire

    ImprimisRx to Focus on Investments in Quality at the 2019 American Academy of Ophthalmology Meeting

    ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (HROW), today announced its participation at the upcoming 2019 American Academy of Ophthalmology (AAO) Annual Meeting to be held at the Moscone Center in San Francisco, CA, October 12-15. The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons, encompassing a community of 32,000 medical doctors. As an FDA-registered and FDA-inspected outsourcing facility, ImprimisRx has made and continues to make significant investments in equipment, processes and personnel to comply with these standards.

  • GlobeNewswire

    Harrow Health to Attend Lake Street’s 3rd Annual Best Ideas Growth Conference September 12, 2019

    Harrow Health, Inc. (HROW) today announced that it will be attending Lake Street’s 3rd Annual BIG Conference September 12, 2019. Please contact your Lake Street representative to arrange a meeting.  Alternatively, to receive additional information, request an invitation or to schedule a one-on-one meeting, you may also email conference@lakestreetcm.com or call 612-326-1305. Founded in 2012, Lake Street Capital Markets is a full-service boutique investment bank focused on dynamic high-growth companies and sectors of the economy.

  • GlobeNewswire

    Harrow Health Announces Second Quarter 2019 Results

    NASHVILLE, Tenn., Aug. 14, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the second quarter 2019. Second Quarter 2019 and Other Recent Notable.

  • GlobeNewswire

    Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics

    NASHVILLE, Tenn., Aug. 02, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today announced that its newly formed subsidiary, Stowe Pharmaceuticals, Inc., has entered into an.

  • GlobeNewswire

    Harrow Health Announces Launch of Mayfield Pharmaceuticals

    NASHVILLE, Tenn., July 31, 2019 -- Harrow Health, Inc. (NASDAQ: HROW), today announced it has filed a Form 8-K with the Securities and Exchange Commission containing a.

  • GlobeNewswire

    Harrow Health to Announce Second Quarter 2019 Financial Results on August 14, 2019

    Harrow Health, Inc. (HROW) today announced it will release second quarter 2019 financial results after the close of trading on Wednesday, August 14, 2019.  The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30 p.m. Pacific Daylight Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (844) 602-0380 for domestic callers or (862) 298-0970 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Harrow Health website by clicking here.  A dial in replay of the call will be available until September 14, 2019.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 51861.  The webcast replay will be available until November 14, 2019.

  • GlobeNewswire

    Harrow Health Adds Two Senior Executives to its Nashville Team

    NASHVILLE, Tenn., June 25, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it has promoted Dennis Saadeh, PharmD as its Chief of Formulation Strategy and has.

  • GlobeNewswire

    Harrow Health, Inc to Locate Headquarters in Nashville, Tennessee

    Tennessee Governor, Bill Lee, Department of Economic and Community Development Commissioner Bob Rolfe and Harrow Health, Inc (HROW) announced today that the company will locate its headquarters operations in Nashville. The new facility will operate as the company’s headquarters and will house the company’s executive positions.

  • PR Newswire

    Novel Drug Solutions, LLC and Eye Care Northwest, PA Terminates Agreement with Harrow Health, Inc.

    ROSELAND, N.J., May 30, 2019 /PRNewswire/ -- Axiom Communications, on behalf of Novel Drug Solutions, LLC and Eye Care Northwest, PA announced today that the companies have delivered a Notice of Termination and Cease and Desist directive to Harrow Health, Inc. (NASDAQ: HROW formerly known as Imprimis Pharmaceuticals, Inc.).

  • GlobeNewswire

    Harrow Health Announces Renegotiated Debt Facility with SWK Holdings

    Harrow Health, Inc. (HROW) today announced it has amended its loan agreement with SWK Funding LLC and its partners.  SWK Funding LLC is a subsidiary of SWK Holdings Corporation, a healthcare-focused investment firm.

  • GlobeNewswire

    Harrow Health Announces First Quarter 2019 Financial Results

    The company’s management team will host a conference call and audio-only webcast today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial results and other recent developments.  To participate in the call, please dial (844) 602-0380 for domestic callers or (862) 298-0970 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Harrow Health website by clicking here.  A dial in replay of the call will be available until June 9, 2019.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 48440.  The webcast replay will be available until August 9, 2019.